CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...

Ironwood Pharmaceuticals, Inc. IRWD along with partner Allergan AGN announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

– The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – “This latest ANDA settlement with Teva reinforces our belief in the strength of the LINZESS ...

On Oct 16, we issued an updated research report on Ironwood Pharmaceuticals, Inc. IRWD. This biopharmaceutical company, based in Cambridge, MA, is focused on the development and commercialization of ...

There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation (CIC) market. And the way some industry watchers see it, it may not be long before the ...

– Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – ...

Ironwood Pharmaceuticals Inc. (NASDAQ: NASDAQ:IRWD) held its Q3 2024 Investor Update Conference Call, announcing a 13% year-over-year increase in prescription demand for its leading product LINZESS.

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults. According ...